Matsukawa Yoshihisa, Majima Tsuyoshi, Matsuo Kazuna, Funahashi Yasuhito, Kato Masashi, Yamamoto Tokunori, Gotoh Momokazu
Department of Urology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Int J Urol. 2018 Mar;25(3):246-250. doi: 10.1111/iju.13489. Epub 2017 Nov 22.
To investigate the effects of tadalafil on storage and voiding function in treatment-naïve patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia, based on a urodynamic study.
This was an open-labeled, single-center, prospective study. A total of 80 untreated outpatients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia received tadalafil 5 mg/day for 12 weeks. Subjective symptoms and objective findings on voiding and storage function obtained through urodynamic studies, including cystometry and pressure flow study, were evaluated before and after treatment.
A total of 71 patients with a mean age of 70.2 years and a mean prostate volume of 45.6 mL were included in the analysis. In the International Prostate Symptom Score and Overactive Bladder Symptom Score, mean total scores significantly improved from 18.2 to 13.4 (P < 0.001) and 6.5 to 4.7 (P < 0.001), respectively, after treatment. Mean maximum bladder capacity significantly increased by approximately 35 mL (P < 0.001). Detrusor overactivity disappeared in 15 (39.5%) of 38 patients with detrusor overactivity at baseline (P < 0.001). Mean maximum flow rate on pressure flow study significantly increased from 7.1 to 9.1 mL/s (P < 0.001) and mean bladder outlet obstruction index significantly decreased from 61.3 to 47.1 (P < 0.001).
Treatment with tadalafil 5 mg once daily effectively relieves lower urinary tract symptoms based on objective improvement of storage and voiding function, such as detrusor overactivity and bladder outlet obstruction, in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
基于尿动力学研究,探讨他达拉非对初治的提示良性前列腺增生的下尿路症状患者储尿和排尿功能的影响。
这是一项开放标签、单中心的前瞻性研究。总共80例提示良性前列腺增生的未经治疗的下尿路症状门诊患者接受每日5毫克他达拉非治疗,为期12周。通过尿动力学研究(包括膀胱测压和压力流率研究)获得的排尿和储尿功能的主观症状和客观结果在治疗前后进行评估。
分析纳入了71例患者,平均年龄70.2岁,平均前列腺体积45.6毫升。治疗后,国际前列腺症状评分和膀胱过度活动症症状评分的平均总分分别从18.2显著改善至13.4(P<0.001)和从6.5显著改善至4.7(P<0.001)。平均最大膀胱容量显著增加约35毫升(P<0.001)。38例基线时有逼尿肌过度活动的患者中,15例(39.5%)的逼尿肌过度活动消失(P<0.001)。压力流率研究中的平均最大尿流率从7.1显著增加至9.1毫升/秒(P<0.001),平均膀胱出口梗阻指数从61.3显著降低至47.1(P<0.001)。
对于提示良性前列腺增生的下尿路症状患者,每日一次服用5毫克他达拉非进行治疗可有效改善储尿和排尿功能(如逼尿肌过度活动和膀胱出口梗阻),从而缓解下尿路症状。